WD Rutherford LLC Lowers Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

WD Rutherford LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,564 shares of the medical research company’s stock after selling 155 shares during the period. Charles River Laboratories International comprises about 2.0% of WD Rutherford LLC’s portfolio, making the stock its 17th largest position. WD Rutherford LLC’s holdings in Charles River Laboratories International were worth $3,946,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC grew its position in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares during the period. Operose Advisors LLC bought a new position in Charles River Laboratories International during the third quarter worth about $42,000. Brown Brothers Harriman & Co. boosted its position in Charles River Laboratories International by 76.0% during the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $62,000. Finally, Bruce G. Allen Investments LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $70,000. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Barclays assumed coverage on shares of Charles River Laboratories International in a research report on Friday. They set an “equal weight” rating and a $230.00 target price for the company. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. TD Cowen cut their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. Finally, Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $254.50.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

CRL traded down $0.77 on Friday, reaching $206.58. The company had a trading volume of 666,758 shares, compared to its average volume of 479,353. The business has a 50 day simple moving average of $220.16 and a 200 day simple moving average of $232.48. The company has a market cap of $10.64 billion, a price-to-earnings ratio of 24.30, a P/E/G ratio of 1.96 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).